HUTCHMED (China) Ltd
HCM17.325USD
+0.055+0.32%
交易中 （美東）報價延遲15分鐘
15.10B總市值
--本益比TTM
關於 HUTCHMED (China) Ltd 公司
和黃醫藥（中國）有限公司是一家主要從事藥品生產及銷售的投資控股公司。公司通過兩個分部經營業務。腫瘤免疫學分部從事用於治療癌症和免疫性疾病的靶向療法和免疫療法的發現、開發和商業化。其中，研發（R&D）包括涵蓋藥物發現、開發、製造和監管職能的研發活動、內部開發藥物的對外授權以及支持研發運營的行政活動，營銷產品包括研發活動開發的藥物的發票銷售、營銷、製造和分銷。其他業務分部從事其他商業業務，包括其他處方藥和保健產品的銷售、營銷、製造和分銷。
公司簡介
公司代碼HCM
公司名稱HUTCHMED (China) Ltd
上市日期May 19, 2006
CEODr. Weiguo Su, Ph.D.
員工數量1811
證券類型Ordinary Share
年結日May 19
公司地址48th Floor, Cheung Kong Center, 2 Queen's Road Central
城市
上市交易所Hochiminh Stock Exchange
國家Hong Kong
郵編- -
電話85221281188
網址https://www.hutch-med.com/
公司代碼HCM
上市日期May 19, 2006
CEODr. Weiguo Su, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Graeme Allan Jack, CPA
Mr. Graeme Allan Jack, CPA
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Mr. David Ng
Mr. David Ng
Vice President
Vice President
--
--
Ms. Ling Yang
Ms. Ling Yang
Non-Executive Director
Non-Executive Director
--
--
Dr. Weiguo Su, Ph.D.
Dr. Weiguo Su, Ph.D.
Chief Executive Officer, Chief Scientific Officer, Executive Director
Chief Executive Officer, Chief Scientific Officer, Executive Director
--
--
Dr. Zhenping Wu, Ph.D.
Dr. Zhenping Wu, Ph.D.
Executive Vice President - Pharmaceutical Sciences and Manufacturing
Executive Vice President - Pharmaceutical Sciences and Manufacturing
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Chig Fung (Johnny) Cheng
Mr. Chig Fung (Johnny) Cheng
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
33.74K
--
Dr. Dan Eldar, Ph.D.
Dr. Dan Eldar, Ph.D.
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Graeme Allan Jack, CPA
Mr. Graeme Allan Jack, CPA
Independent Non-Executive Director
Independent Non-Executive Director
--
--
Dr. Chaohong (Mary) Hu
Dr. Chaohong (Mary) Hu
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Kin Hung (Mark) Lee
Mr. Kin Hung (Mark) Lee
Senior Vice President - Corporate Management and Communications
Senior Vice President - Corporate Management and Communications
--
--
Prof. Shu Kam (Tony) Mok
Prof. Shu Kam (Tony) Mok
Independent Non-Executive Director
Independent Non-Executive Director
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2024
FY2023
FY2022
FY2021
FY2020
暫無數據
地區USD
名稱
營收
佔比
PRC
630.20M
0.00%
Unallocated
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月14日 週三
更新時間: 5月14日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Schroder Investment Management (Singapore) Ltd.
1.07%
Schroder Investment Management (Hong Kong) Ltd.
0.56%
Allianz Global Investors Asia Pacific Limited
0.50%
State Street Global Advisors (US)
0.19%
AIA Group Ltd
0.18%
Other
97.49%
持股股東
持股股東
佔比
Schroder Investment Management (Singapore) Ltd.
1.07%
Schroder Investment Management (Hong Kong) Ltd.
0.56%
Allianz Global Investors Asia Pacific Limited
0.50%
State Street Global Advisors (US)
0.19%
AIA Group Ltd
0.18%
Other
97.49%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
2.54%
Investment Advisor
0.77%
Hedge Fund
0.25%
Research Firm
0.21%
Individual Investor
0.12%
Bank and Trust
0.03%
Sovereign Wealth Fund
0.01%
Other
96.05%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
157
6.88M
3.95%
-6.42M
2025Q1
166
6.98M
4.00%
-6.73M
2024Q4
187
7.28M
4.18%
-8.01M
2024Q3
259
7.73M
4.44%
-16.35M
2024Q2
280
9.29M
5.33%
-17.79M
2024Q1
306
15.01M
8.61%
-19.39M
2023Q4
327
16.63M
9.55%
-27.28M
2023Q3
339
25.00M
14.36%
-20.50M
2023Q2
352
26.00M
15.01%
-20.74M
2023Q1
364
26.52M
15.33%
-22.52M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Schroder Investment Management (Singapore) Ltd.
1.87M
1.07%
+570.74K
+43.88%
Mar 31, 2025
Schroder Investment Management (Hong Kong) Ltd.
972.00K
0.56%
-496.17K
-33.80%
Mar 31, 2025
Allianz Global Investors Asia Pacific Limited
945.74K
0.54%
-117.52K
-11.05%
Mar 31, 2025
State Street Global Advisors (US)
336.87K
0.19%
-10.74K
-3.09%
Mar 31, 2025
AIA Group Ltd
315.44K
0.18%
--
--
Mar 31, 2025
M&G Investment Management Ltd.
258.69K
0.15%
-7.09K
-2.67%
Mar 31, 2025
Jane Street Capital, L.L.C.
222.24K
0.13%
+124.77K
+128.01%
Mar 31, 2025
Su (Weiguo Ph.D.)
183.98K
0.11%
+183.98K
--
Mar 04, 2024
UBS Financial Services, Inc.
165.47K
0.09%
-212.26K
-56.19%
Mar 31, 2025
Amundi Asset Management, SAS
157.43K
0.09%
-12.82K
-7.53%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
National Security Emerging Markets Index ETF
0.37%
ProShares Ultra Nasdaq Biotechnology
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
ActivePassive International Equity ETF
0%
SPDR Portfolio Developed World ex-US ETF
0%
National Security Emerging Markets Index ETF
佔比0.37%
ProShares Ultra Nasdaq Biotechnology
佔比0.05%
Invesco Nasdaq Biotechnology ETF
佔比0.05%
ActivePassive International Equity ETF
佔比0%
SPDR Portfolio Developed World ex-US ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
